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Summary 
Self-peptides bound to HLA-DR4 (DRA-DRBl*0405 complex) were eluted from the purified 
DR4 complex, ffactionated on reverse-phase  HPLC, and subjected to NH2-terminal sequencing. 
Seven independent sequences were obtained,  and all putative  peptides  synthesized bound to 
DRBI*0405 as well as DRBI*0406 complex, which differ only at DRfl residues 37,  57, 74, 
and 86. Binding assay using analogue peptides of a DR4 binder GSTVFDNLPNPE revealed 
that FxxLxN is an important anchor motif necessary for binding (where x is any amino acid), 
which was common to DRBI*0405 and 0406. Determination of the binding affinity of  60 synthetic 
AAFAALANAA-based analogue peptides showed that substituting F to W  or C; L to F, W, 
or Y; and N to Q or S on AAFAALANAA  changed the affinity substantially between DRBI*0405 
and DRBI*0406.  It is noteworthy that all patients with methimazole-induced insulin autoimmune 
syndrome are positive for DRBI*0406 and negative for DRBI*0405.  Interestingly, the quantitative 
structural motif identified in this study predicted that 8TSICSLYQLE  17 of human insulin cx chain 
may bind specifically  to DRBI*0406 using its l~  motif. Indeed, DRBI*0406 complex 
bound sTSICSLYQLE17 with a high affinity, and in striking contrast, DRBI*0405 complex did 
not. Furthermore, a short-term T cell line specific  to human insulin established  from a DRBI*0406- 
bearing individual did show reactivity with a peptide fragment containing the l~  motif. 
Although this fragment probably exists at a very low level under normal physiological conditions 
due to the disulfide bond between flanking cysteine residues (6Cys-llCys), a reducing compound 
such as methimazole may cleave  the disulfide bond in vivo and allow DRcr-DRBI*0406 complex 
on antigen-presenting  cells to bind much of the linear fragment of insulin c~ chain, which may 
lead to the activation of self-insulin-specific T-helper cells. 
p~  cognition of peptide fragments in the context of class 
II MHC molecules by T cells is a central event in the 
development of immune responses. Proteolytic fragments of 
peptides processed by APC that match the physicochemical 
character of the peptide-binding grooves formed by c~ and 
/3 chains of class II MHC molecules are expressed on the sur- 
face of APC and are recognized by T cells (1). However, the 
peptide-binding  grooves of most stable MHC molecules are 
occupied by self-peptides (2), and most T cells are tolerized 
or ignorant against these peptides except in autoimmune con- 
ditions. 
The amino acid residues in the grooves of the HLA class 
II molecules are highly polymorphic, indicating that genetic 
polymorphism accounts for the wide spectrum of peptides 
capable of binding.  Among the HLA dass II genes, DRB1 
coding for DRfl chains has the highest degree of polymor- 
phism, and appears to be responsible for variations in the im- 
mune responses of different individuals to different antigens. 
Among these, DR4 has 14 subtypes designated DRBI*0401 
through DRBl*0414 with slight differences in the structure 
of the peptide-binding  groove, thus allowing detailed anal- 
yses of peptide-DR interactions. 
DRBI*0405 is the most common DR4-associated subtype 
(30%  in antigen frequency) among Japanese, yet it is also 
unique to Orientals. In Caucasians, the most common DR4 
subtype is DRBI*0401 which differs from DRBI*0405 at 
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strongly associated with rheumatoid arthritis (RA)  1 among 
both Japanese and Caucasians.  However, in the Japanese,  the 
relative  risk of RA associated  with DRBI*0405  is higher 
than with DRBI*0401. Furthermore, DRBI*0401, but not 
DQ genes in linkage disequilibrium, reportedly play a major 
genetic role in the development of RA (3). On the contrary, 
DRBI*0406, another DR4 subtype unique to Orientals that 
differs from DRBI*0405  at four residues,  does not confer 
susceptibility to RA but rather to insulin autoimmune syn- 
drome (IAS)  (4). 
The structural motif of peptides capable  of binding to 
HLA-DR. have been determined based on non-self-peptide 
sequences  capable  of stimulating T  cells in the context of 
DR, and on self-peptide sequences eluted from purified DR 
complexes with (5-8) or without (9, 10) peptide-DR binding 
assay. Phage peptide libraries have also been used to identify 
HLA-binding motifs (11, 12). Some of these reports suggested 
that only certain residues are involved in allele-specific pep- 
tide binding, whereas  the other residues  are promiscuous 
(9, 12). 
In  the  current  study,  we  not  only detail  the  elution, 
purification, and sequencing of naturally processed self-peptides 
bound to  purified DR4  (DRBI*0405)  complex, but  also 
quantitatively demonstrate a structural motif of the DR4 
(DRBI*0405 and DRBl*0406)-binding peptides.  Moreover, 
through binding assays using a series of polyalanine-based 
peptides with single amino acid substitutions, we identified 
the conserved residues for the allele-specificity and promiscuity 
of  peptide-DR4 interactions. Based on these data, allele-specific 
interactions between DR4 subtypes and peptide fragments 
derived from human insulin, an autoantigen recognized by 
T  cells in IAS are analyzed. 
Materials and Methods 
Cells and HLA  Typing.  HLA-DR4 complexes were isolated 
from EBV-transformed  human B lymphoblastoid cell lines EBWa 
and KT13 (13) homozygous for HLA-DRBI*0405 or DRBI*0406, 
respectively. The cell line was maintained in vitro at 37~  in 5% 
CO2 by culture  in  RPMI  1640 (GIBCO  BILL, Gaithersburg, 
MD), containing 10% heat-inactivated  FCS, 2 mM glutamine, and 
antibiotics. HLA-DR alleles of the B lymphoblastoid cells as well 
as PBMC donors used for a generation of an insulin-specific  T cell 
line were determined by investigating hybridization between HLA- 
DR genes amplified by polymerase chain reaction and sequence 
specific oligonucleotide probes, as described elsewhere (14). 
Isolation of HLA-DR4.  Cells  were lysed in 1% NP-40/PBS, 
containing 5 mM sodium orthovanadate, 25 mM iodoacetamide, 
and 1 mM PMSF as described elsewhere (15). The supernatants 
of the resulting homogenate were precleared first by normal mouse 
v-globulin-bound  Sepharose and  second by protein  A-bound 
Sepharose. The effluent was applied for affinity chromatography 
1 Abbreviations used in this paper: IAS, insulin  autoimmune  syndrome;  ICso, 
concentration  for 50% inhibition;  MIF, migration  inhibitory  factor;  PKM2, 
pyruvate kinase, M2  isozyme; RA,  rheumatoid arthritis; 0405BP, 
DRBI*0405 complex binding peptide. 
with a mAb HU-4 (anti-DR  IgG2a; 13,  16), which was previ- 
ously shown to precipitate  DRc~DR3(B1) but not DRoeDR3(B4) 
complex (13). The HU-4 column was made by using ImmunoPure 
IgG Orientation  Kit  (Pierce, Rockford,  IL)  according to  the 
manufacturer's instructions. The column was washed sequentially 
with 30 bed volumes of 0.5% NP-40, 0.1% SDS/PBS, and 15 bed 
volumes of 1% n-octyl-glucoside/PBS.  The DR-peptide complex 
was eluted with 1% n-octyl-glucoside,  50 mM diethylamine, and 
0.15 M NaC1, at pH 10.5, immediately  neutralized  with half volume 
of 0.1 M Tris and 0.15 M NaC1 at pH 6.8 (17), and then precipi- 
tated by acetonitrile at a final  concentration of 80%. Seven cycles 
of purification with a total of 20 g  (10  l~ cells) of EBWa cells 
yielded a total of 900 #g of purified DR4 molecules  as determined 
by SDS-PAGE. These DR preparations did not exhibit visible  bands 
at dye fronts on 11% SDS-PAGE. The DRBI*0406 complex was 
purified from KT13 cells in the same manner. 
Separation of Selfpeptides and DR Molecules.  Dried acetonitrile 
precipitates were dissolved in 2.5 M acetic acid and incubated for 
30 rain at 37~  The solution was centrifuged in a Centricon-10 
(10-kD cut-off; Amicon Corp., Danvers, MA) to separate DR4 
and oligopeptides. Centrifugation was repeated twice with graded 
additions of 2.5 M acetic acid to increase the yield of self-peptides, 
and the filtrate was concentrated on a Speed Vac (Savant Instru- 
ment Inc., Farmingdale, CA) to 100/zl. The buffer of the acid- 
treated DR fraction was exchanged  to I mM PMSF, 0.05% NP-40, 
5% DMSO, and 0.15 M NaC1 in 50 mM phosphate buffer, pH 7.0, 
by repeated addition of the buffer and centrifugation, until the pH 
value of the filtrate remained at 7.0. The DR preparation in a neu- 
tral buffer thus obtained was either immediately used for DR-pep- 
tide binding assay  in the presence of protease inhibitor cocktail or 
kept frozen at  -80~  until assay. 
Purification of Self-peptides on HPLC.  The acid-eluted  crude self- 
peptide fraction obtained from DRBI*0405 complex was loaded 
onto a 2.1  x  150 mm C18 reverse-phase HPLC column (Waters 
Assoc., Milford, MA) equilibrated with 0.06%  TFA and 5% 
acetonitrile in water. The column was eluted at a flow rate of 0.25 
ml/min at room temperature in a gradient of increasing acetoni- 
trile concentration in 0.052% TFA with the absorption at 214 and 
280 nm (A214 and Azs0) continuously monitored. 
Sequence Analyses and Peptide Synthesis.  Sequencing by Edman 
degradation was performed in a pulsed liquid sequencer (477A) 
equipped with an on-line phenylthiohydantoin  amino acid analyzer 
(120A; both models from Applied Biosystems, Foster City, OIL). 
All peptides used for the binding assay  were synthesized  by a solid- 
phase simultaneous  multiple peptide synthesizer  (PSSM-8; Shimadzu 
Corp., Kyoto,  Japan) based on the Fmoc strategy.  All peptides were 
purified by C18 reverse-phase  HPLC. Purified  peptide 0405BP3 was 
sequenced to confirm its structure. 
DR-Peptide  Binding Assay.  The  DR-peptide  binding  assay 
was performed as described elsewhere with minor modifications 
(18). Briefly, purified DR was incubated for 48 h with 20 nM 
12SI-labeled peptides in a total volume of 50 #1, and in some ex- 
periments, with various doses of various unlabeled peptides, in 
the presence of a protease inhibitor  cocktail. Purified peptides 
were radioiodinated using Iodobeads (Pierce Chem. Co., ). The 
solution used for incubation  was: i mM PMSF, 1.3 mM 1.10  phenan- 
throline, 73 #M pepstatin A, 8 mM EDTA, 6 mM N-ethyl malei- 
mide, 200/zM N-oe-p-tosyl-r-lysine  chloromethyl ketone, 0.05% 
NP-40, 5% DMSO, and 0.15 M NaC1 in 50 mM phosphate buffer 
at pH 7.0. The DR-peptide  complexes were separated from free 
peptides by gel filtration  on a Sephadex  G-50 (Pharmacia  Fine Chem- 
icals, Piscataway,  NJ) column (4 x  120 ram) equilibrated with 0.5% 
NP-40, 0.1% NaN3/PBS, and the fractions were assayed for ra- 
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calculated as the ratio of peptide in the void volume to the total 
peptide recovered, as described by O'Sullivan et al. (18). 
Binding Inhibition Assay.  Peptide  inhibitors were added to DR. 
molecules at the same time as radioiodinated 0405BP3. Peptide in- 
hibitors were typically tested at concentrations ranging from 500 
#M to 50 nM. The data were then plotted, and the concentration 
which yielded 50% inhibition (IC50) of binding was determined. 
Generation of a Human T Cell Line Specific to Insulin.  PBMC 
(5  x  10Vml) of a DRBl*0406-bearing  individual were pulsed 
with 50 ~M of human recombinant insulin (I-0259; Sigma Chem- 
ical Co., St. Louis, MO) in the presence of 5 x  10 .5 M of 2-mer- 
captoethanol overnight at 37~  in 5%  COJ95%  of air with 
humidified atmosphere. The stock solution of insulin was prepared 
first by adding 5 mM of 2-mercaptoethanol to reduce insulin. These 
cells were then washed and incubated (1  x  10S/well) in a 96-well 
flat-bottomed culture plate. 7 d after stimulation, cells were fed 
with insulin-pulsed, irradiated autologous PBMC (1  x  10S/well) 
in the presence of recombinant human IL-2 (50 U/ml) and IL-4 
(10 U/ml). Cells were incubated for 7 d after feeding and the T 
cell blasts were transfered to a 24-well plate to be expanded  by feeding 
and incubation for 7 d. To investigate a proliferative response to 
insulin peptides of the T cell line, viable T cell blasts were sepa- 
rated by Ficoll-Paque (Pharmacia Fine Chemicals) density gradient 
and incubated (3  x  104/well)  for 72 h with irradiated autologous 
PBMC (1.0 x  105/well) and soluble synthetic peptides (5/~M) in 
a 96-well plate, in the presence of [3H]thymidine during the final 
16-h period. Cells were then harvested  and subjected  to liquid scin- 
tillation counting. 
Results 
Purification and Sequencing of  Self-peptides Eluted from HLA- 
DR4 (DRBI*0405).  Self-peptides  eluted from 900/ig of 
purified DR4 (DRBI*0405) were separated by reverse-phase 
HPLC. The resulting chromatogram (Fig. 1) showed marked 
clustering of signals between 60 and 80 min, which correspond 
to 22 and 32% acetonitrile concentrations in the eluates, respec- 
tively.  The experiment was repeated with another 900/ig 
of purified DR preparation,  and a similar pattern was ob- 
tained. Edman degradation of these fractions yielded eight 
definitive sequences long enough for a homology search (Table 
1).  Of these eight sequences,  peaks 4,  5,  6,  7,  and 8 were 
idehtified as fragments of CD23,  CD20,  migration inhibi- 
tory factor (MIF), pyruvate kinase,  and CD23, respectively, 
by homology search with the SWISS-PROT database R26.0 
(Table 1). Peak 8 was presumably derived from CD23 closer 
to the amino terminus than peak 4. The origins of the other 
three peptides were not identified. Because of limited quan- 
tity of peptides used for sequencing,  all eight peptides tended 
to show unidentifiable low signals towards the COOH ter- 
mini; therefore, it seems likely that all peptides were longer 
than shown in Table 1. 
Detection of  Peptide-DR Binding by Inhibition Assay.  Three 
peptides  (PKM2p99-117  [SDPILYRPVAVALDTKGPE], 
0405BP3  [GSTVFDNLPNPEIDGDYYGW], and 0405BP1 
[VPIQRAVYQNVVVNN])  were  selected  for  the  direct 
binding assay because  of the presence  of Tyr residues  for 
radioiodination, and the following results were obtained (data 
not shown):  (a)  all three peptides were tested for binding 
with DRBI*0405 and DRBI*0406 complexes, and exhibited 
10-20%  of DR-binding activity at pH 7.0,  whereas an ir- 
relevant  peptide (NELSGEAHKDALGKLY) did not show 
any significant binding; (b) the binding affinity of these pep- 
tides to DR4 complexes  at pH 4 was lower than that at pH 
7; and (c) of the three synthetic peptides, 0405BP3  exhibited 
the highest percent binding to both the DRBI*0405  and 
DRBI*0406 complexes.  To this binding assay system, var- 
ious concentrations of either unlabeled 0405BP3  peptide or 
an irrelevant peptide were added and the percent binding in- 
hibition (percent inhibition) was determined. As shown in 
Fig. 2, the coexistence of unlabeled 0405BP3  competitively 
inhibited the binding of iodinated 0405BP3 to the DR4 com- 
plexes in a dose-related manner, whereas the irrelevant pep- 
tide did not. 
Eluted  Self-peptides  All  Bind  to  the  DRBI*0405  and 
DRBl*0406  Complexes.  By using the competitive inhibi- 
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Figure 1.  HPLC chromato- 
gram with  crude mixture of 
DRBl*0405-binding  peptides. 
Acid-eluted  small  peptide  fraction 
was  separated on C18  reverse- 
phase HPLC  with A214 continu- 
ously  monitored.  Retention  times 
of 60 and 80 min correspond to 
22 and 32% acetonitrile  in eluates, 
respectively. 
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Homology 
Peak 
number  Sequence* (upper)  and 
homologous peptide  (lower) 
1  VP I QRAVYQNVVVNNPXD 
2  SPGTGAYYVLLN 
3  GSTVFDNLPNPE I DGDYYGW 
4  XGQLVS INN 
E  ......  HSPEEQDFLTKHA  (CD23p195-214) 
5  GPKPLFRRM 
SSLVGPTQSFF  (CD20p26-45) 
6  XXXQY I AVHVVPDQT 
GKPP---  LMAFG  (MIFp32-51) 
7  SDP I LYRPVAVALD 
TKGPE  (PKM2p99-117) 
8  XEGQLVS I 
HSPEEQDFLTKHA  (CD23p195-214) 
* Eight peaks shown in Fig. 1 were sequenced by Edman degradation. 
Peak numbers correspond to those in Fig. 1. Lower line of each peak 
number indicates the most homologous sequence  in the SWISS-PROT 
database R26.0 followed  by a protein name and residue number. (-) In- 
dicates a residue identical with that obtained by sequencing. 
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Figure 2.  Detection of peptide-DtL4  binding by inhibition assay. The 
.  r162  .  DRB1 0405 complex (open c~rcle)  or DKBI  0406 complex (closed  circle) 
were incubated  for 48 h with various concentrations of unlabeled 0405BP3 
(GSTVFDNLPNPEIDGDYYGW) in  the  presence of radioiodinated 
0405BP3 (20 riM). Peptides bound to DR4 complexes were quantitated 
as the total radioactivity  in the void volume on a Sephadex G-50 column. 
Percent inhibition relative to the radioactivity obtained in the absence of 
competitor peptide was determined. An irrelevant peptide (NELSGEAHK- 
DALGKLY) tested as a competitor revealed nearly identical results either 
with DRBI*0405 or with DRBI*0406 (closed  square). 
tion assay thus established, we tested if isolated self-peptides 
bind  to  the  DR4 complexes.  In  addition  to the 0405BP3 
peptide shown in Fig. 2, 0405BP1, PKM2p99-117, CD20p26- 
45,  CD23p195-214,  MIFp32-51,  and 0405BP2  (SPGTGA- 
YYVLLN) were incubated with the DRBI*0405 complex 
in the presence of radioiodinated 0405BP3. The results shown 
in Table 2 clearly show that all seven peptides competitively 
inhibited  the  binding  of labeled 0405BP3  peptide  to  the 
DRBI*0405  complex  (59-103%  inhibition),  whereas  the 
irrelevant peptide did not (1% inhibition).  Thus, these data 
strongly  suggest  that  all  the  peptides  shown  in  Table  1 
were natively bound to the peptide-binding  groove of the 
DRBI*0405 complex, and were not co-purified contaminants. 
Furthermore,  these peptides showed affinity not only to the 
DRBI*0405 from which they were originally derived, but 
also to the DRBI"0406  complex. However, the affinity of 
0405BP1, 0405BP2, PKM2p99-117,  and MIFp32-51 to the 
DRBI*0406 complex were significantly lower than that to 
the DRBI*0405 complex, suggesting heterogeneity in pep- 
tide binding  between these two DR4 complexes. 
Binding of Single Amino Acid-substituted  DR4 Binder to the 
DRB1*0405 and 0406.  We then truncated the carboxy ter- 
minus of the 0405BP3 peptide and identified by titration  a 
12 met (GSTVFDNLPNPE) that binds to the DRBI*0405 
complex as efficiently as the original 0405BP3 peptide (titra- 
tion shown in Fig. 4). This also indicates that iodinated Tyr 
residues on 0405BP3 are not involved in binding to the DR4 
complex. To identify the structural motif of the DR4-binding 
peptides, we synthesized a series of nonconservatively modified 
peptides  of the  truncated  0405BP3  with  the  hydrophilic 
residues on 1GSTVFDNLPNPE12 substituted to Ala, and at 
position 2,  hydrophilic  Ser was substituted  to Val because 
of the structural  similarity between Ala and Ser. To avoid 
introducing side chains too large to fit in the groove or charged 
side groups generating  repulsive interactions,  hydrophobic 
residues  were substituted  to  small neutral  hydrophilic  Ser 
residues.  As shown in Fig.  3 a,  only two nonconservative 
substitutions (F to S and L to S) completely eliminated pep- 
tide binding to the DRBI*0405 complex. In addition, while 
substitution of 10th N  to A inhibited binding by 70%, the 
adjacent substitution  of P  to S inhibited  the binding only 
slightly. Furthermore, exactly the same pattern was obtained 
by using the DRBI*0406 complex (Fig. 3 b). These results 
revealed a putative structural "backbone" of .... F- - L-N(P)-, 
which plays a crucial role in the binding of 1GSTVFDNLP- 
NPE 12 to the DR4 complexes. 
Competition Assay with Polyalanine Design Peptides.  To de- 
termine which residues are required for high affinity binding 
to the DR4 complexes, we synthesized a polyalanine-based 
10-met analogue (AAFAALANAA) of 0405BP3, and tested 
its affinity to the DRBI*0405 and the DRBI*0406 complexes. 
As shown in Fig. 4,  the polyalanine-based peptide affinity 
to both DRBI*0405 (Fig. 4 a) and DRBI*0406 (Fig.  4 b) 
complexes  was  equal  to  that  of the  truncated  0405BP3 
(GSTVFDNLPNPE).  The same results were obtained with 
a 12-mer analogue, AAAAFAALANAA (not shown). The 
results confirmed that  the affinity of these peptides are the 
same  as  the  original  0405BP3  (GSTVFDNLPNPEIDG- 
876  DRBI*0405-  and DRBI*0406 Binding Peptide Motifs Table  2.  Binding  of Eluted Self-peptide to DRB1 *0405 and DRB1 *0406 Complexes 
Unlabeled synthetic peptide as an inhibitor* 
Percent inhibition for binding to 
DRBI*0405  DRBI*0406 
Irrelevant peptide (NELSGEAHKDALGKLY) 
0405BP1 (VP I QRAVYQNVVVNN) 
0405BP2  (SPGTGAYYVL  LN) 
0405BP3 (GSTVFDNLPNPE I DGDYYGW) 
PKM2p99-117 (SDPI LYRPVAVALDTKGPE) 
CD20p26-45 (GPKPLFRRMSSLVGPTQSFF) 
CD23p195-214 (EGQLVS I HSPEEQDFLTKHA) 
MIFp32-51 (GKPPQY  t AVHVVPDQTMAFG) 
1  2 
103  70 
93  85 
97  96 
90  71 
90  96 
59  63 
94  69 
* Purified DR.4 complexes  were incubated for 48 h with 20 nM of 1251-0405BP3  with or without various unlabeled peptides (20/xM). The DR-peptide 
mixtures were then separated on a Sephadex G-50 column. Total radioactivity of peptide bound to DR molecules was obtained by subtracting the 
corresponding chromatography fractions run in the absence of DR. Percent inhibition was calculated based on the total radioactivity obtained in 
the absence of competitive inhibitors. 
DYYGW) shown in Fig. 2. These results indicate that: (a) 
the FxxLxN (where x is any amino acid) motif plays a cru- 
cial  role in  the  binding  of 0405BP3  peptide  to  both  the 
DRBI*0405  and DRBI*0406  complexes; and (b) the pos- 
sible minor compartment of 11th proline (Fig. 3) could be 
replaced by alanine. 
To identify other structural motifs, 60 peptides with sub- 
stitutions of the F, L, or N  residues of AAFAALANAA  to 
R.,  K,  H,  E,  D,  Oo  N,  T,  S, C,  G, A,  V,  L,  I,  F,  M,  W, 
Y, P, or hydroxyproline were synthesized and evaluated by 
binding inhibition  assay with DRBI*0405  and 0406 corn- 
a  b 
%Inhibition with DRBI*0405  %Inhibition  with DRBI*0406 
Unlabeled peptide  50  100  50  100 
Irrelevant pe~ide 
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A  ........... 
S  ........... 
-A  .......... 
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--A  ......... 
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...........  A 
0.i~s  0:s 
Figure 3.  Binding  of single amino acid-substituted DR4 binder to the 
DRBI* 0405 (a) and DRB1 "0406 (b) complexes.  Peptides  with single  amino 
acid substitutions based on truncated 0405BP3 (GSTVFDNLPNPE)  were 
synthesized and tested on a binding inhibition assay at 5/xM. (-) Indi- 
cates a residue without substitution. Larger percent inhibition indicates 
better binding to DP-.4. Substitutions yielding less than 50% inhibition 
(i.e., ICs0 more than 5/~M) and corresponding residues on the original 
peptide are boxed. 
plexes.  For quantitative evaluation, the IC50 for each pep- 
tide was determined, where a lower value indicates better 
binding.  As shown in Fig. 5 a, substitutions of the first an- 
chor caused marked variation in IC50 values. Thus, only hy- 
drophobic  residues  showed  detectable  binding  to  the 
DRBI*0405  or 0406 complex. With Trp in this position, 
the  IC50  for DRBI*0405  was  less  than  10%  of that  for 
DRBI*0406. Conversely, hydrophilic residues at the first an- 
chor could not bind to either DR4 complex except for Cys 
which had a weak affinity to the DRBI*0405 complex. Al- 
though substitutions to hydrophobic residues exhibited the 
highest  affinity  at  the  second  anchor,  certain  nonbasic 
hydrophilic amino acids also showed affinity (Fig. 5 b). Among 
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Figure 4.  Competition  assay with  polyalanine  design peptides. 
DRB1 *0405 (a) and DRB1 *0406 (b) were incubated with various con- 
centrations of GSTVFDNLPNPE  (closed  square) and AAFAALANAA (open 
circle) in the presence of radioiodinated 0405BP3, and percent inhibition 
was determined. 
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RKHEDQNTSCGAVL  IFMWYP 
RKHEDQNTS  CGAVL  I FMWYP 
Table  3.  Binding of Polyalanine-based Peptides to DR4 
IC50 with 
Synthetic peptide 
as a competitor*  DRBI*0405  DRBI*0406 
AAFAAMASAA  3.6  1.1 
AALAAIASAA  11.0  8.8 
AAYAALANAA  1.4  5.0 
KAAYAAVAVAA  5.1  12.2 
AAKAAKAGAA  >500  >5~ 
* Polyalanine-based peptides were incubated at various concentrations with 
DR4 complexes in the presence of 1731-0405BP3 (20 nM) and IC50 values 
were  determined.  KAAYAAVAVAA  was  derived from  0405BPl, 
MIFp32-51, and PKM2p99-117. AAFAAMASAA, AALAAIASAA, and 
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Figure  5.  Binding spectrum of AAFAALANAA-based single amino 
acid-substituted peptides. (a) The first anchor "F" of AAFAALANAA 
was substituted to various amino acid residues (abscissa)  and their ICs0 
values (pA,/) against the binding of 1~I-0405BP3 with DRBI*0405 (open 
rectangle  with solid line) and DRBl*0406 (shaded  diamond  with shaded  line) 
complexes were determined. A smaller ICs0 indicates better binding. (b) 
The second anchor "E' of AAFAALANAA was substituted and the same 
assay was performed. (c) The third anchor "N" of AAFAALANAA was 
substituted and the same assay was performed. 
tral  Set  had  the  lowest  affinity,  which  was comparable to 
SLeu to SSer substitution  of 1GSTVFDNLPNPE12  shown in 
Fig. 3. Phe, Trp, or Tyr bound preferentially to DRBI*0405. 
The third anchor was more promiscuous than either the first 
or second anchor (Fig.  5 c). Thus, although the IC50 of the 
most  favored (N  and  S for DRBI*0405  and 0406,  respec- 
tively) and least favored (Q and G for DRBI*0405 and 0406, 
respectively) substitutions differed by as much as several hun- 
dredfold,  all  the  substitutions,  including  basic  hydrophilic 
residues, showed detectable binding to both DP,4 complexes. 
Interestingly,  unlike  the  other  anchors,  residues  such as Q 
or S revealed significantly higher binding with DRBI*0406 
(IC50 less than 10%  of 0405).  When substituting  the third 
anchor to hydrophobic residues, Lys was inserted in the amino 
terminus of the peptide to increase its solubility.  This inser- 
tion does not create a new binding  motif because lysine in 
the first anchor had no affinity to the DR4 complexes (Fig. 
5 a). Hydroxyproline exhibited practically the same levels of 
affinity as proline at all three anchor positions (not shown). 
Binding of Polyalanine-based  Peptides Based on Eluted Self-peptide 
Sequences.  The above quantitative  structural  motif for the 
DR4 binders allowed us to identify the putative amino acid 
residues important  for binding on the eluted DRBI*0405- 
Table  4.  Binding of Insulin-derived Synthetic Peptides to DR4 
Insulin-derived peptide* 
IC50 with 
DRBI*0405  DRBI*0406 
K-Instep1-10  (KG I VEQCCTS I) 
KK-Ins~p8-17 (KKTS I CSLYQLE) 
K-Insotp12-21 (KSLYQLENYCN) 
K-Ins3pl-18  (KFVNQHLCGSH LVEALYLV) 
K-Ins3p11-30  (KLVEALYLVCGERGFFYTPKT) 
>500  >500 
180  4.1 
10.5  12.0 
>500  >500 
15.0  14.5 
* Human insulin-derived synthetic peptides were incubated at various concentrations with DR4 complexes in the presence of 1251-0405BP3 (20 nM) 
and IC50 values (/zM) were determined.  One to two residues of Lys were inserted at the amino termini to increase the solubility. 
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the  DRBl*0405-binding  peptides  (except  0405BP3),  are 
AAFAAMASAA,  AALAAIASAA,  AAYAALANAA,  and 
AAYAAVAVAA. These motifs were synthesized and tested 
by  binding  inhibition  assay. Since  the  putative  motif of 
AAYAAVAVAA for 0405BP1,  MIFp32-51,  and PKM2p99- 
117 was not soluble, lysine was inserted at the NH2 terminus 
(KAAYAAVAVAA)  to  increase  the  solubility.  Indeed,  as 
demonstrated in Table 3, all the polyalanine-based peptides 
bound to both DE4 complexes whereas AAKAAKAGAA, 
which was predicted from Fig. 5 to show null binding, had 
no  affinity.  This  also indicates  that  there  is  no detectable 
binding with the AxxAxA motif. The YxxVxV and YxxLxN 
motifs did not show very high affinity to the DRBI*0406 
compared with DRBI*0405 complex, confirming the results 
shown in Table 2 and Fig.  5.  Thus,  Tyr at the first anchor 
reduces the  affinity to DRBI*0406. 
Identification of Human Insulin Fragment That Binds Prefer- 
entially to DRBI*0406.  Using the above structural motifs 
for the DE4 binders, we searched for a human insulin frag- 
ment with a higher affinity to the DRBI*0406 than to the 
DRBI*0405 complex, since such a fragment may be recog- 
nized by T  cells of patients with IAS. As shown in Fig.  5, 
such a motif is likely to have Q  or S as its third anchor. In- 
terestingly,  the o~ chain does have an IxxLxQ motif which 
contains a cysteine residue. To confirm allele specificity of the 
binding, sTSICSLYQLE17 and other insulin fragments were 
synthesized and tested for binding affinity to the DR4 com- 
plexes. Table 4 shows the IC50 values for these peptides with 
DRBI*0405 and 0406. As predicted by the quantitative struc- 
tural  motif,  TSICSLYQLE  has  the  highest  affinity to  the 
DRBI*0406 complex, with an ICs0 value 44 times smaller 
than that  for the DRBI*0405.  Since this insulin fragment 
forms  a disulfide bond between flanking  cysteine residues 
(6o0, reducing agents such as methimazole may linearize  this 
fragment by cleaving the disulfide bond. Insulin/~p11-30 and 
otp12-21  could  also  bind  with  lower  affinities  both  to 
DILBI*0406  and  to  0405,  but  the  motif in  this  location 
(~24FxxTxm~29 and ~t3LxxLxN  c~18, respectively) did not con- 
tain cysteine residues (Fig.  6).  No other insulin  fragments 
bound to either Dl~,4 complex. 
13 chain 
FVNQHLCGSHLVEALYLVCGERGFFYTPKT 
I  \  e-rw,  Q cTs s  , YcN 
a  chain 
F,gure  6.  DRB1 0406-bmdmg  motifs  on human insulin. IxxLxQ  motif 
with the most effictent  binding to DRB1 0406 complex  ,s boxed. Other 
binding motifs (FxxTxK and LxxLxN) are underlined. Lines  between  cys- 
teine residues indicate disulfide bonds. 
Identification of Human Insulin Fragment That Stimulates the 
Autoreactive T  Cell Line Specific to Insulin.  To test whether 
DRBl*0406-bearing individuals carry T cells autoreactive to 
the insulin peptide with the IxxLxQ motif, we established 
a  short-term  T  cell line  by stimulating  PBMC  with  the 
recombinant  human  insulin.  With  the  established  T  cell 
line exerting  insulin-induced  proliferation,  we  quantitated 
the T cell reactivity against each synthetic peptide. As shown 
in Table 5, the T cells showed the strongest reactivity against 
Inso~p8-21  (STSICSLYQLENYCN21)  which  contains  both 
IxxLxQ  and  LxxLxN  motifs.  The  T  cells  proliferated  in 
response  to  Insotp8-19  (sTSICSLYQLENy19)  but  not  to 
Instep8-17 (8TSICSLYQLEt7),  which is devoid of the third 
anchor  N  of the  LxxLxN  motif.  However, this  may not 
indicate that  the T  ceils  are recognizing  the DIk4-peptide 
complex through a preferential usage of LxxLxN motif for 
binding,  since the T  cells are capable of recognizing amino 
acid residues lying 8 to 9 residues apart to the carboxy ter- 
minus from the first anchor  (1). Thus,  it is likely that  the 
truncation  of t8NYCN2t affected the T  cell recognition  of 
the DR4-peptide  complex formed by using  not  only the 
LxxLxN but also the IxxLxQ motif. On the contrary, trun- 
cation of four residues of Insotp8-21 at the amino terminus 
(Insotpl2-21;  x2SLYQLENYCN21) clearly dissects these two 
binding motifs, because the first anchor (necessary for binding 
to DR4 as shown in Fig. 3) lie of the IxxLxQ motif is removed 
whereas the LxxLxN motif is kept intact. Stimulation with 
this truncated peptide decreased the T cell response by 66% 
as compared with  Insap8-21.  These  observations indicate 
that the  binding  through  the  IxxLxQ  motif rather  than 
Table  5.  T  Cell Reactivity against Human Insulin Fragments 
Synthetic  peptide*  Sequence  Percent  T  cell response 
KK-Insc~p8-21  KKTS I_CSLYQLENYCN  lOO 
KK-Ins~xp8-19  KKTS I_CSLYQLENY  89.0 
KK-Insc~p8-17  KKTS I CSLYQLE  0.3 
K-Insc~pl2-21  KS_LYQLENYCN  33.8 
K-InsBpll-30  KLVEALYLVCGERGFFYTPKT  32.1 
*  A  short-term autoreactive T cell line established by stimulating PBMC from a DRBl*0406-bearing individual with reduced human recombinant 
insulin was incubated with autologous irradiated PBMC in the presence of various soluble synthetic peptides, and subjected  to [3H]thymidine incor- 
poration assay. The IxxLxQ motif is underlined. The following formula was used to calculate the percent T cell response using mean values of 
duplicate cultures. Percent T cell response =  100 x ([cpm with a peptide] -  [cpm without peptide])/([cpm with KKIns~pS-21] -  [cpm without 
peptide]). The denominator was 4,514 cpm. 
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complex recognized by the T cells. In addition to the minor 
reactivity against the LxxLxN motif, another weak reactivity 
was detected against Ins3p11-30, which is shown in Table 4 
to bind DR4 complexes with an intermediate affinity. Syn- 
thetic peptides such as Insc~pl-10 that exhibited no detect- 
able binding to DR4 complexes (Table 4) were devoid of 
T  cell-stimulating activity (not shown). 
Discussion 
In the studies herein, we report that:  (a) native DR.oe- 
DRBI*0405 complex purified from B lymphoblastoid cells 
have, in their peptide-binding grooves,  peptide fragments 
of CD23,  CD20, MIF, pyruvate kinase,  and three uniden- 
tified peptides; (b) three amino acid residues  (anchors)  on 
these peptides, such as FxxLxN are important for binding; 
(c) the first  anchor, closest  to the amino terminus of the 
binding peptides, must be hydrophobic; (d) the second an- 
chor,  which is  three residues  apart  from the  first  one is 
hydrophobic but  some  nonbasic  hydrophilic residues  are 
also capable  of binding;  (e)  the  third  anchor,  lying two 
residues apart from the second anchor, is promiscuous but 
the binding affinity  was  variable;  ~  although the basic 
motif for  binding  to  DRBI*0406  is  similar  to  that  for 
DRBI"0405, certain residues reveal a significant  difference 
in binding requirements; (g) anchor residues on DR4 binders 
are predictable; (h) among human insulin-derived peptide 
fragments,  the  8TSICSLYQLE17 of the human insulin el 
chain,  which is exposed only under reducing conditions, 
has the highest affinity  specific to DRBI*0406 by binding 
with the IxxLxQ motif; and (i) a short-term human insulin- 
specific T  cell line generated from a DRBl*0406-bearing 
individual recognizes  a  peptide  fragment  containing  the 
IxxLxQ motif as a major T  cell epitope. 
The reasons insulin peptide binding is thought to occur 
in the grooves include: (a) negative binding of 0405BP3 in 
reducing conditions eliminated nonspecific "stickiness" of the 
peptide to the DR complexes (not shown), and (b) some 
binders  with  low  ICs0  (good binders)  co-cultured  with 
DRBI*0405- and 0406-restricted T cell clones inhibited the 
antigen-specific proliferative responses (manuscript in prepa- 
ration). 
Because polymorphic residues of DR alleles are scattered 
within the peptide-binding grooves, different DR molecules 
are capable of binding peptides with different structural motifs, 
and this phenomenon contributes to the HLA-linked poly- 
morphism of immune responses. To date, motifs for binding 
peptides have been reported in DR1 (DRBI*0101; 5, 8, 10, 
11), DR2 (DRB1*1501;  8, 9), DR3 (DRBI*0301; 6, 7, 9), 
DR.4 (DRBI*0401; 9, 12, 19), DR11 (DRBl*1101; 8, 12), 
DR7 (DRBI*0701; 8, 9,  20),  and DR8 (DRBI*0801; 9). 
The structural motif for DR4 (B1"0405  and 0406) binders 
clarified in the current study showed significant  similarity 
to a DRBl*0401-binding motif reported by Hammer et al. 
(12), but not to one reported by Chicz et al.  (9). The dis- 
crepancy probably arose from the different strategies by which 
the structural motifs were identified. Although Chicz et al. 
aligned  the  sequences  without  performing  DR-peptide 
binding assay, the DRBl*0401 binders reported in their study 
all have the basic motif  proposed herein. Indeed, solely aligning 
the sequences of the seven self-peptides shown in Table I led 
to three possible motifs such as hydrophobic-x-x-x-hydro- 
phobic, which failed to show high affinity binding with the 
DR4 using polyalanine-based  peptides (not shown). These 
data collectively indicate that the DR-peptide binding assay 
is necessary to identify the structural motifs of DR-binding 
peptides. 
Structural motifs reported previously confirmed that sero- 
logically distinguishable DR alleles such as DR1, DR3, and 
DR4 have distinct binding motifs (6,  12). However,  quite 
a  few immune responses  of humans or  susceptibility to 
immunity-related  diseases have been shown to be allele specific, 
even among alleles that can only be distinguished at  the 
DNA level. For instance, DRBI*0405 confers increased sus- 
ceptibility to  RA  but  not  to  IAS,  whereas  serologically 
identical DRBI*0406  conversely  confers  susceptibility to 
IAS but not  to RA  (3,  4)  among Japanese.  This type of 
discrepancy was explained based on peptide-HLA interactions 
in the current study; the basic  structural motif is similar 
between DRBI*0405 and 0406, but the allele specificity of 
peptide binding is determined by differences in affinity to cer- 
tain amino acid residues at the important anchor positions. 
In view of the reports that anti-HLA alloantisera can recog- 
nize not only the structure of the peptide-binding grooves 
but also bound peptides existing within the grooves  (21), 
it is likely that serologically  indistinguishable alleles (e.g., 
DR4 subtypes) physiologically bind analogous sets of self- 
peptides. Indeed, although native DRBl*0406-binding pep- 
tides were not sequenced in this study, all the peptides eluted 
from the DRBI*0405  could bind to the DRBI*0406 com- 
plex with variable affinity. 
The IC50 cannot be used to directly assess DR-peptide 
affinity among different studies because of the different con- 
centrations of 125I-labeled  peptide applied. However, regardless 
of the  relatively  high  IC50,  the Ka  value  for 0405BP3- 
DRBI*0405 interaction calculated from the data shown in 
Fig. 2 was 70 nM, approximately the same level of DR-pep- 
tide affinity reported by others (18). Of the seven self-peptides 
eluted from the DRBI*0405 shown in Table 1, a motif for 
the  CD23  fragment (LxxlxS)  did  not  show very strong 
binding, as predicted by the quantitative structural motif. 
However,  because of the abundant expression of CD23 on 
EBV-transformed B lymphoblastoid cells, it is conceivable 
that this fragment existed within the groove at a detectable 
level. 
The first anchors on binding peptides shown in Fig. 5 a 
were strictly hydrophobic, which is concordant with other 
reports (12). The hydrophobic pocket formed by the oe helix 
of the DRoe and DR3 chains is probably responsible for the 
hydrophobic interaction (1). Among amino acid residues on 
DR complexes presumably involved in this interaction, only 
S6DR3 is polymorphic among the DR4 subtypes. In a com- 
parative study with DRB1*1101 and 1104, Demotz et al. ob- 
served that glycine on S6DR3 is capable of accommodating 
more species of hydrophobic residues than valine on 86DR  3 
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Thus the DRBI*0405 (glycine on S6DR3), compared with 
the  DRBI*0406  (valine  on  86DR3),  exhibited  higher 
affinity with some of the first anchors on binding peptides 
such as W, C, or Y, whereas none of residues bound prefer- 
entially to DRBI*0406. 
Some of the second anchor residues  also exhibited allele 
specificity in binding, especially with F, W, or Y. The closest 
polymorphic  site  within  the  groove  should  be  74DRy, 
which is Ala in DRBI*0405 and Glu in DRBI*0406 (23). 
However, the allele specificity of the second anchor cannot 
be fully explained solely by the interaction with 74DRy, be- 
cause none of the basic residues (R, K, or H) exhibited high 
affinity  binding with  the DRBI*0406  (Glu  for 74DRy). 
Possible explanations for this discrepancy include: (a) the side 
chains of basic amino acid residues  in this position of the 
peptides are too large to fit into the groove; and (b) 74Dr3 
does not directly interact with the second anchor but rather 
affects the three-dimensional and physicochemical character- 
istics of the groove, where the second anchor of DR4-binding 
peptides interacts with HLA (20). The DRBl*0401-binding 
motif reported recently by Sette et al. (19) did not contain 
the second anchor in our current study possibly because: (a) 
their data is based on substitutions of Q  to E, A, H, L, T, 
N, and K which are not favored residues in this position for 
DRBl*0405-peptide interactions; and/or (b) there is a sig- 
nificant difference between DRBI*0401 and DRBI*0405 in 
this position. However, their observation that K in this posi- 
tion is the least favored substitution agrees with our results. 
Unlike the first  and  second anchors,  none of the sub- 
stitutions in  the  third  anchor  completely eliminated the 
binding. However, this position conceivably plays an impor- 
tant role in high affinity binding because single amino acid 
substitution analysis using another DR4 binder 0405BP2 
(1SPGTGAYYVLLN12) showed the importance of this po- 
sition. Thus, substitution of 7th Y  and 10th L (SPGTGA- 
YYVLLN) to Ser residues completely eliminated the binding 
to DRBI*0405, whereas the same substitutions at 8th Y 
and 11th L (SPGTGAYYVLLN) did not affect the binding, 
presumably by losing the putative third anchor N. Substitu- 
tion of the 12th N to A also affected the binding significantly 
(not shown). These data indicate that the third anchor is 
necessarly for binding to DR4. In this regard, Hammer et al. 
(12) reported that polyalanine-based  1YAALAAAAL9 pep- 
tide bound to DRBI*0101, 0401, and 1101. Moreover,  sub- 
stitution of 6Ala to Thr or Arg, which exactly corresponds 
to the third anchor in the current study, clearly resulted in 
allele-specific binding, with Thr having the highest affinity 
to the DRBI*0401 complex. In light of the structural sim- 
ilarity between DRBI*0401 and 0405, this observation cor- 
roborates the results of the present study. 
Recent crystallographic analysis of a DRl-peptide (3~ 
YVKQNTLKLAT  31s) complex by Stern et al.  (23) clearly 
supports the current observations.  Thus, the side chains of 
308y, 311Q, 313T, and 314L, which correspond exactly to 5F, 
SL, l~  and tip on tGSTVFDNLPNPE12, respectively, are 
buried in the pockets formed by residues containing many 
polymorphic sites. Some previous studies on DR-binding 
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motifs suggested the existence of another important hydro- 
phobic anchor lying eight residues from the first anchor (12, 
19, 20), which is also buried in a small pocket that was re- 
vealed by crystallography (23). However, the importance of 
this anchor was not confirmed in the present study because: 
(a) truncated 0405BP3 that lacks this position had the same 
affinity as the original 0405BP3;  and (b) of the seven DR4 
binders analyzed in this study, two did not even have this 
position, and those which did have it did not show any definite 
residue selectivity at this position. It might be that the de- 
gree of the involvement of this possible anchor in DR-pep- 
tide interactions may depend on the DR alleles mad binding 
peptides, as demonstrated by Hammer et al. (12). It is espe- 
cially important to note that acidic residues (Asp or Glu) in 
this position prevent interaction with DRBI*0401 according 
to Sette et al. (19), although three DRBl*tM05-binding pep- 
tides (PKM2p99-117,  CD23p195-214, and MIFF32-51 ) ana- 
lyzed in our current study have acidic residaes in the position. 
Among the polymorphic residues,  57DRB, which forms a 
banklike side wall of a pocket accomodating 316L of 3~ 
VKQNTLKLAT  31s  (23),  is  acidic  (Asp)  in  I)RBI"040I 
(thus causing repulsive interaction with acidic residues which 
enter the groove), whereas it is neutral (Sea:) in DRBI*0405. 
The small neutral side chain of Ser at this position should 
accommodate a greater variety of amino acid residues since 
steric hindrance and repulsive ionic interactions are smaller. 
Thus it is likely that this polymorphism plays a major role 
in the existence or variability of peptide binding at a resi&ie 
lying eight residues  apart from the first anchor. 
Some polyalanine-based peptides, such as AALAAIASfiA 
had slightly higher affinity to DR4 than the original pep- 
tides. It may be that the native sequence contains amino acid 
residue(s),  which inhibit binding as reForte~ by Boehncke 
et al. (24), and substitution to alanine rem~es this inhibi- 
tion. Single amino acid substitution to alan~e on antigenic 
peptides is frequently applied in studies on MHC-peptide 
and TCR-MHC/peptide interactions; however, this stratesy 
might occasionally lead to incorrect results because, as shown 
in Fig.  5, alanine clearly plays a rote in the interaction be- 
tween HLA and peptide fragments. In this sense, the strategy 
for the identification of anchor positions shown ir~ Fig: 3 (de- 
tection of decreased binding by substitution 'to A or S) can 
only be applied to peptides that exhibit wry high-affinity 
binding with HLA. Fortunately, F, L, and N of AAFAAL- 
ANAA revealed significantly higher affinity than A or S in 
all the three positions, which allowed us to identify these 
anchors by observing decreased binding. Negligible differ- 
ences in affinity  among AAFAALANA/~, GSTVFDNLP- 
NPE, and the original 0405BP3 also ruled out possible over- 
sight of important anchor residues. However, if this strategy 
is used for a low-affinity peptide, extensive substitutions in 
all the positions (19, 20) might be necessary to avoid missing 
critical anchors. Indeed, our present study on extensive sub- 
stitutions of streptococcal  M12 peptide recognized by a T 
cell clone in the context of DRBI*0406 did not reveal any 
other anchor positions for the binding with DRBI*0406 com- 
plex (manuscript in preparation). 
IAS is characterized  by a large amount of total serum- immunoreactive insulin, the presence of anti-insulin autoan- 
tibodies, and fasting hypoglycemia, and is reported to be the 
third leading cause of hypoglycemia among Japanese (25). 
Another interesting feature of IAS is that one-quarter of the 
patients had been taking medication prior to the onset, 94% 
of which were sulphydryl compounds such as methimazole, 
mercaptopropionyl glycine, or glutathione. The direct associ- 
ation of DRBI*0406 with IAS (relative risk =  281) was suc- 
cessfully explained in this study by quantitative comparison 
of DRBI*0406- and 0405-binding peptide motifs. Thus, three 
human insulin-derived synthetic peptides showed detectable 
binding to DRBI*0406  complex, among which the most 
efficient binder otp8-17, has the IxxLxQ motif that preferen- 
tially binds to the DRBI*0406 complex due to the presence 
of Gln at the third anchor. Moreover, this sequence has  a 
cysteine residue in the middle of the binding motif (ICSLYQ), 
which  forms  a  disulfide  bond  with  the  flanking  obCys 
residue.  Therefore, in view of the clinical observations,  it 
is conceivable that  insulin  czp8-17  is  a  reduction-induced 
DRBl*0406-specific  cryptic self. 
In this respect however, a recent study by Ito et al.  (26) 
showed that even T cells of DRBl*0406-bearing healthy in- 
dividuals can proliferate in response to human insulin presented 
by the DRBI*0406 complex, whereas T cells of  DRBI*0405- 
bearing healthy individuals cannot. This observation is sup- 
ported by another report that APC have a reducing capacity 
to some extent (27,  28).  Thus,  the insulin fragment with 
disulfide bond(s) may not be "cryptic" in a strict sense, but 
rather the cleaved insulin fragment may exist within APC 
at a low level in physiological conditions, against which self- 
tolerance is not completely acquired. Forced reduction of in- 
sulin probably augments this immune response and transmits 
intense "helper"  signals  to  B  cells  for  the production  of 
autoantibody  to  self-insulin.  Other  fragments,  /~p11-30 
and otp12-21, could also bind with lower affinities  to both 
DRBI*0406 and 0405 nearly equally, presumably with their 
#24FxxTxm/~29 and a13Lxx.LxNalS motifs, respectively.  It may 
be that these possible T cell epitopes exist physiologically at a 
level sufficient to acquire partial self tolerance, because the 
O24FxxTxmO29 and ~13LxxLxNalS motifs, as well as flanking 
residues,  contain no disulfide bonds, and can be recognized 
by T cells in the context of HLA molecules without forced 
reduction. Indeed, the unexpected minor T cell reactivity ob- 
served against these fragments might be explained by the de- 
velopment of anti-insulin autoantibody through T cell rec- 
ognition of otp8-19 (Table 5), by which B cells can be involved 
more efficiently in the presentation of insulin molecules to 
T cells. In light of the equal affinity of the fragments con- 
taining  the  ~24FxxTxK~29 and  al3LxxLxN  cds  motifs  to 
DRBI*0405 and DRBI*0406 (Table 4), the observation that 
T cells from DRBl*0405-bearing individuals do not proliferate 
at all in response to insulin (26) may support this hypothesis. 
Another possible factor for DR-peptide binding is the sub- 
strate specificity of lysozomal proteases for antigen processing. 
The extent, if any, of polymorphism in this regard remains 
obscure. However, insulin ot chain after S-S cleavage may be 
short enough to be presented without the involvement of 
proteases (9,  29). 
The quantitative identification of structural motifs shown 
in this study not only facilitate the understanding of allele- 
specific binding of self- or non-self-peptides to HLA mole- 
cules but also help in the prediction of the hierarchy of  binding 
affinity of multiple T cell epitope sites on natural protein an- 
tigens.  In this regard, human collagen type II, one of the 
most likely autoantigens to be recognized by T cells in RA 
(30), has 11 possible sequences (not counting proteolytic sites) 
for binding to the DRBI*0405 complex. Studies are underway 
to: (a) determine T cell precursor frequency by stimulating 
T cells of DRBl*0406-bearing patients with IAS and healthy 
subjects using synthetic human insulin fragments; and (b) 
establish T  cell clones from RA patients recognizing pos- 
sible DRBl*0405-binding  fragments of collagen type II. 
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